Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The influence of ibrutinib on progression-free survival and complete survival

Simon Rule, MD from Derriford Hospital, Plymouth, UK outlines his presentation on his work with ibrutinib. Prof Rule discusses the outcome of a compilation of three trials involving the single-agent ibrutinib in 307 patients with relapsed/refractory mantle cell lymphoma. In these trials the response by baseline criteria, characteristics, progression free-survival (PFS) and complete survival were analyzed. It was known previously that ibrutinib has a 70% response rate, consequently instead these trials concentrated on progression-free survival and complete survival. Results showed that if ibrutinib is used at first relapse the results are hugely more significant in comparison to use in second or third line treatment. Furthermore when looking at complete remission (CR) the duration of response is impressive, with 92% of patients alive two years after treatment. Finally Prof Rule discusses the response of patients with poor prognostic factors of mantle cell lymphoma to ibrutinib. The trials showed that although response the same, these patients progression-free survival is inferior. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.